

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. - 18. (Cancelled)

19. (Currently Amended) A method of treating a hyperphosphatemic condition in a mammal, said method comprising administering to a mammal afflicted with the disorder a therapeutically effective amount of an isolated FGF20 polypeptide comprising the amino acid sequence of SEQ ID NO:1.

20. (Currently Amended) The method of claim 19, wherein, the isolated FGF20 polypeptide consists of the amino acid sequence of SEQ ID NO:1 ~~comprises a mutation that confers increased stability to said FGF20 polypeptide.~~

21. - 24. (Cancelled)

25. (Currently Amended) A method of treating a condition involving deposition of calcium and phosphate in the arteries or soft tissues of a mammal, said method comprising administering to said mammal a therapeutically effective amount of FGF20 an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1 ~~or a reagent that increases the level of FGF20~~ polypeptide.

26. (New) The method of claim 25, wherein, the isolated polypeptide consists of the amino acid sequence of SEQ ID NO:1.

27. (New) The method of claim 19, wherein said mammal has a serum phosphate level greater than 5.0 mg/dL.

28. (New) The method of claim 25, wherein said mammal has a serum phosphate level greater than 5.0 mg/dL.
29. (New) The method of claim 19, wherein said isolated polypeptide is administered by intravenous injection.
30. (New) The method of claim 25, wherein said isolated polypeptide is administered by intravenous injection.
31. (New) The method of claim 25, wherein said soft tissue is muscle tissue.
32. (New) A method of treating a hyperphosphatemic condition in a mammal, said method comprising administering to a mammal afflicted with the disorder a therapeutically effective amount of a purified variant of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1, wherein the variant is purified in *E. coli*.
33. (New) The method of claim 32, wherein said mammal has a serum phosphate level greater than 5.0 mg/dL.
34. (New) The method of claim 32, wherein said isolated polypeptide is administered by intravenous injection.
35. (New) A method of treating a condition involving deposition of calcium and phosphate in the arteries or soft tissues of a mammal, said method comprising administering to said mammal a therapeutically effective amount of a purified variant of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1, wherein the variant is purified in *E. coli*.
36. (New) The method of claim 35, wherein said mammal has a serum phosphate level greater than 5.0 mg/dL.

Applicant: Shimkets *et al.*
U.S.S.N. 10/644,349

37. (New) The method of claim 35, wherein said isolated polypeptide is administered by intravenous injection.

38. (New) The method of claim 35, wherein said soft tissue is muscle tissue.